Skip to main content

Novus Biologicals products are now on

Better as one

Recombinant Human Dystroglycan Fc Chimera Protein, CF

Catalog # 10223-DG | R&D Systems, Inc. a Bio-Techne Brand
Catalog #
Size / Price

Key Product Details



Accession #

Structure / Form

Disulfide-linked homodimer





Product Specifications


Human embryonic kidney cell, HEK293-derived human Dystroglycan protein
Human Dystroglycan
Accession # Q14118
N-terminus C-terminus


>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gln313 (blocked) of alpha chain and Ser654 of beta chain

Predicted Molecular Mass

68 kDa (alpha subunit) & 37 kDa (beta subunit)


70-100 kDa and 120-135 kDa (alpha subunit) & 45-55 kDa (beta subunit)


Measured by the ability of the immobilized protein to enhance the adhesion of H4 human neuroglioma cells.
The ED50 for this effect is 1.5-9 μg/mL.

Scientific Data Images for Recombinant Human Dystroglycan Fc Chimera Protein, CF

Recombinant Human Dystroglycan Fc Chimera Protein Bioactivity

Recombinant Human Dystroglycan Fc Chimera Protein Bioactivity

Immobilized Recombinant Human Dystroglycan Fc Chimera (Catalog # 10223-DG) enhances the adhesion of H4 human neuroglioma cells. The ED50 for this effect is 1.5-9 μg/mL.

Formulation, Preparation and Storage

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 2 weeks, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Dystroglycan

Dystroglycan, also called DAG1 (dystrophin‑associated glycoprotein 1) or DG, is a heterodimeric adhesion molecule that links the extracellular matrix (ECM) to the cell cytoskeleton (1‑4). Human DAG1 is a type I transmembrane protein that is initially expressed as a large prepro protein. Autocatalysis of the proform produces two fragments (an alpha and beta chain) that remain noncovalently‑linked. The alpha chain (aa 28-653) contains a mucin‑like region, while the beta chain (aa) consists of an extracellular domain, a transmembrane region, and a cytoplasmic domain (5). Over aa 28-749, human DAG1 shares 93% aa sequence identity with mouse DAG1. DAG1 is widely expressed but differentially O‑glycosylated on skeletal muscle and epithelia (which contain a 160 kDa alpha ‑chain) as compared to cardiac muscle, smooth muscle, fibroblasts, keratinocytes, lymphocytes, and hematopoietic stem cells (which contain a 100‑140 kDa alpha ‑chain) (1‑3, 6‑9). DAG1 binding of ECM molecules is influenced by its alpha ‑chain O‑glycosylation (2, 6‑10). In addition to skeletal muscle and neuromuscular junctions in which DAG1 binds several ECM molecules, DAG1 is important for neuronal migration (through neurexin interactions), keratinocyte attachment to the ECM (through laminin), and adhesion at the immunological synapse and in the hematopoietic stem cell niche (through agrin) (3, 6‑11). In muscle, the beta ‑chain cytoplasmic domain connects with the cytoskeleton via formation of the dystrophin‑glycoprotein complex with isoforms of dystrophin, sarcoglycan, syntrophin, and sarcospan (3). This complex is critical for skeletal muscle viability and regeneration (3, 4, 10, 11). MMP9 cleavage of the 44 kDa beta ‑chain creates a 30 kDa transmembrane form that causes dissociation of the heterodimer and a down‑regulation of ECM interactions (6, 12). Dystroglycanopathies, a group of congenital muscular dystrophies affecting the brain, eye and skeletal muscle, are caused by either abnormalities in glycosyltransferases, or their accessory proteins, or rare DAG1 polymorphisms. All result in DAG1 hypoglycosylation, especially of O‑mannosyl forms, and affect DAG1 binding to ECM proteins (2, 3, 10, 13, 14).


  1. Ibraghimov-Bedkrovnaya, O. et al. (1993) Hum. Mol. Genet. 2:1651.
  2. Godfrey, C. et al. (2011) Curr. Opin. Genet. Dev. 21:278.
  3. Barresi, R. and Campbell K.P. (2006) J. Cell Sci. 119:199.
  4. Durbeej, M. and K.P. Campbell (1999) J. Biol. Chem. 274:26609.
  5. Akhavan, A. et al. (2008) FASEB J. 22:612.
  6. Herzog, C. et al. (2004) J. Invest. Dermatol. 122:1372.
  7. Leonoudakis, D. et al. (2010) J. Cell Sci. 123:3683.
  8. Zhang, J. et al. (2006) FASEB J. 20:50.
  9. Mazzon, C. et al. (2011) Blood 118:2733.
  10. Michele, D.E. et al. (2002) Nature 418:417.
  11. Cohn, R.D. et al. (2002) Cell 110:639.
  12. Bozzi, M. et al. (2009) IUBMB Life 61:1143.
  13. Yoshida-Moriguchi, T. et al. (2010) Science 327:88.
  14. Hara, Y. et al. (2011) N. Eng. J. Med. 364:939.

Long Name

Dystrophin-associated Glycoprotein 1

Alternate Names

AGRNR, Dag-1, DAG1

Entrez Gene IDs

1605 (Human); 13138 (Mouse); 114489 (Rat)

Gene Symbol



Additional Dystroglycan Products

Product Documents for Recombinant Human Dystroglycan Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Dystroglycan Fc Chimera Protein, CF

For research use only

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Setting the standard in quality research reagents